Sebia, a world leader in multiple myeloma diagnostics and monitoring, has introduced M-inSight its serum-based Minimal Residual Disease (MRD) test for monitoring in multiple myeloma. M-inSight is a Laboratory Developed Test (LDT) being offered by Corgenix, part of the Sebia Group.

Polpharma Biologics, an international biotech company focused on developing and manu­facturing biosimilars, has received approval from the European Commission for Tyruko (natalizumab) as the first and only biosimilar for relapsing forms of multiple sclerosis (MS) in Europe. Tyruko was developed by Polpharma Biologics and will be commercialized by its collaboration partner Sandoz.

Shimadzu has released the AIMsight infrared microscope. AIMsight builds on the high sensitivity of Shimadzu’s well-known AIM-9000 to offer an improved operational experience through greater automation. AIMsight is intended for industrial applications, such as drug manufacturing.

INTEGRA Biosciences has launched MIRO CANVAS, a compact digital microfluidics platform for fully automated next generation sequencing (NGS) sample preparation. The revolutionary system significantly simplifies NGS workflows for more walk-away time and higher lab productivity.